Definium Therapeutics (NASDAQ:DFTX) Earns Buy Rating from Analysts at Bank of America

Stock analysts at Bank of America initiated coverage on shares of Definium Therapeutics (NASDAQ:DFTX) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $75.00 price target on the stock. Bank of America‘s target price indicates a potential upside of 65.71% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. Robert W. Baird increased their price objective on Definium Therapeutics from $57.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Royal Bank Of Canada boosted their price objective on shares of Definium Therapeutics from $57.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Finally, Leerink Partners set a $52.00 price target on Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $63.00.

Definium Therapeutics Stock Performance

DFTX opened at $45.26 on Tuesday. The business’s 50-day simple moving average is $40.27 and its 200 day simple moving average is $27.09. Definium Therapeutics has a 52-week low of $8.70 and a 52-week high of $49.70. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The firm has a market capitalization of $6.08 billion, a PE ratio of -13.20 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, sell-side analysts expect that Definium Therapeutics will post -2.81 earnings per share for the current fiscal year.

Insider Activity at Definium Therapeutics

In other Definium Therapeutics news, insider Mark Sullivan sold 13,008 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the transaction, the insider directly owned 320,571 shares in the company, valued at $14,435,312.13. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Matthew T. Wiley sold 2,867 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the transaction, the insider directly owned 174,633 shares in the company, valued at $7,863,723.99. The trade was a 1.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. raised its holdings in Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after acquiring an additional 3,020 shares during the period. Caxton Associates LLP bought a new stake in shares of Definium Therapeutics during the third quarter worth approximately $126,000. Mercer Global Advisors Inc. ADV grew its position in shares of Definium Therapeutics by 10.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after purchasing an additional 2,079 shares during the last quarter. Finally, Scientech Research LLC acquired a new position in shares of Definium Therapeutics in the third quarter valued at approximately $286,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.